Skip to main content

ADMA BIOLOGICS, INC.

corporate_fare Company Profile

ADMA BIOLOGICS, INC.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ADMA - Latest Insights

ADMA
Apr 15, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
ADMA
Mar 28, 2026, 6:18 AM EDT
Source: Access Newswire
Importance Score:
7
ADMA
Mar 27, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
ADMA
Mar 27, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
ADMA
Mar 25, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
ADMA
Mar 02, 2026, 7:13 AM EST
Source: Unknown
Importance Score:
8
ADMA
Mar 02, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
ADMA
Feb 25, 2026, 5:16 PM EST
Filing Type: 10-K
Importance Score:
8
ADMA
Feb 25, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
ADMA
Jan 12, 2026, 8:20 AM EST
Filing Type: 8-K
Importance Score:
8